Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience

Research output: Contribution to journalArticle

Abstract

Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.

Original languageEnglish
Pages (from-to)1489-1493
Number of pages5
JournalAnticancer Research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Bevacizumab
Combination Drug Therapy
Platinum
Liver Transplantation
Pediatrics
Survival
Liver
Therapeutics
Neoplasms

Keywords

  • Bevacizumab
  • Childhood
  • Hepatocellular carcinoma
  • Liver transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{8e5533b99ead4e899c19b7c7eb15cbd9,
title = "Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience",
abstract = "Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.",
keywords = "Bevacizumab, Childhood, Hepatocellular carcinoma, Liver transplantation",
author = "{De Pasquale}, {Maria Debora} and {De Goyet}, {Jean De Ville} and Lidia Monti and Chiara Grimaldi and Alessandro Crocoli and Aurora Castellano",
year = "2017",
month = "3",
day = "1",
doi = "10.21873/anticanres.11475",
language = "English",
volume = "37",
pages = "1489--1493",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma

T2 - A single-center experience

AU - De Pasquale, Maria Debora

AU - De Goyet, Jean De Ville

AU - Monti, Lidia

AU - Grimaldi, Chiara

AU - Crocoli, Alessandro

AU - Castellano, Aurora

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.

AB - Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.

KW - Bevacizumab

KW - Childhood

KW - Hepatocellular carcinoma

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=85015863734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015863734&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11475

DO - 10.21873/anticanres.11475

M3 - Article

C2 - 28314323

AN - SCOPUS:85015863734

VL - 37

SP - 1489

EP - 1493

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -